Health Trials

A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

ConditionPalmoplantar Pustulosis (PPP)
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Eligibility criteria

Qualifiers

None

Disqualifiers

Significant improvement of PPP symptoms between screening and baseline (PPPASI decrease ≥ 5).

Trial design

Treatments tested in this trial

  • Tofacitinib
  • Imatinib
  • tofacitinib Placebo
  • Imatinib Placebo

Treatment groups

135 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

Source ClinicalTrials.gov